Taprenepag isopropyl (PF-04217329) (Synonyms: PF-04217329) |
Catalog No.GC31919 |
Taprenepag isopropyl (PF-04217329) is a highly selective EP2 receptor agonist.
Products are for research use only. Not for human use. We do not sell to patients.
Cas No.: 1005549-94-9
Sample solution is provided at 25 µL, 10mM.
Taprenepag isopropyl is a highly selective EP2 receptor agonist.
Taprenepag isopropyl is a highly selective EP2 receptor agonist. Intraocular pressure (IOP) in the left, vehicle-dosed eye typically remains within the normal range. In the right (Taprenepag isopropyl-dosed) eye, IOP is reduced in all dose groups. In the high-dose group, IOP is reduced to the extent that it cannot be measured (<4mm Hg) on Days 22 and 29. There are no clinical signs or changes in body weight observed with any dose of Taprenepag isopropyl administration, and noocular findings occur for animals in the low-dose group (0.75 mg/day)[1].
[1]. Yanochko GM, et al. Investigation of ocular events associated with taprenepag isopropyl, a topical EP2 agonist in development for treatment of glaucoma. J Ocul Pharmacol Ther. 2014 Jun;30(5):429-39.
Average Rating: 5
(Based on Reviews and 30 reference(s) in Google Scholar.)GLPBIO products are for RESEARCH USE ONLY. Please make sure your review or question is research based.
Required fields are marked with *